Fig. 5: Therapeutic effects of UdAb n425 in mice.
a Schematic design of the biodistribution study in BALB/c mice. Mice (n = 12 mice/group) were intravenously injected via the tail with 5 mg/kg 125I-n425 or 125I-m102.4. Three mice were euthanized at each time point (0, 15, 30, and 60 min) for blood and brain collection. b The antibody concentration in the brain and blood was calculated as a percentage of the injected dose per gram of tissue mass (%ID/g). Data are represented as the mean ± S.D. c Schematic representation of treatment with four types of antibodies in the NiVM pseudovirus-infected mouse model. Suckling mice were intracerebral or intrathoracic (i.t.) inoculated with NiVM pseudoviruses and subsequently treated with PBS. On d 3, the mice were anesthetized for fluorescence examination. d, e Suckling mice were intracerebral or intrathoracic inoculated with NiVM pseudoviruses and subsequently treated with n425, n425-sFc-n425, n425-Fc, or mAb m102.4 via the intraperitoneal route at a dose of 5 mg/kg at 2 h post-challenge. On d 3, the bioluminescence signal for each mouse was detected using the IVIS-Lumina III imaging system. The data are expressed as the means ± S.D. (n = 6 mice per group for intrathoracic infectious model; n = 5 mice per group for intracerebral infectious model). Significant differences between the two independent groups were determined by the Mann‒Whitney U test using Prism software (*, p < 0.05; **, p < 0.01). The illustrations in (a, c) were created with BioRender.com under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International license. Source data are provided as a Source Data File.
